A Confluence of Concerns

I've started wondering about the worrisome overlap of countries affected by the recent tsunami in southeast Asia and reported instances of human infection with Avian Flu (H5N1).  I'm not the only one, fortunately, who is thinking about this.  Henry Niman (who knows much more virology than I) is keeping a list of interesting stories on this over at recombinomics (see the "in the news" section).  There is a 70% mortality rate in humans, which is certainly frightening, and there are now confirmed cases of human-to-human transmission between people living in close quarters, but I think it is important to delve a little deeper into what may be going there.

It isn't yet clear what changes would be necessary in the virus to make it the cause of a true pandemic.  Even the causes of the 1918 "Spanish Flu" are still under debate.  The great concern for H5N1 is that it will recombine with a strain that already easily infects humans.  This has long thought to be the way the Spanish Flu became so deadly, but recently some debate has emerged along the lines that mutation rates in some areas of the hemaggluttinin gene (HA) were accelerated instead.  That is, mutation within the genome, rather than recombination, may have created enough variation to result in the virus that killed tens of millions of people.  In order for recombination to operate, two different virus strains must simultaneously infect the same cell, providing the opportunity to mix their genes.  However, it turns out (see below) that homologous recombination among RNA viruses appears to be a low probability event.

For his part, the good Dr. Niman is quite firm about the role of recombination;

This is the key issue on the influenza pandemic.  The 1918 H1N1 virus gained its lethality by recombining, not reassorting.  The same thing has happened with H5N1.  The H5N1 in Thailand and Vietnam have already picked up pieces of genes that are not in any other H5N1 isolates.  These polymorphisms are found in mammalian isolates such as humans and pigs (and the 1918 isolate had polymorphisms normally found in humans and pigs).

Needless to say, we will never know exactly how the 1918 strain came to be.  But its transformation into a pandemic strain is of definite interest today.

There are stories running around that the 1918 flu was the result of a peculiar set of circumstances. [UPDATE: See my post The Spanish Flu Story.] I have only heard this story as hearsay, so if anyone knows where it came from give a yell (hopefully it isn't from an obvious book I should have read).  Essentially, the story blames the 1918 Flu on World War I.  Large numbers of wounded troops were being removed from disease ridden conditions on the battlefield, and then moved through various hospitals, with the most grievously ill and wounded becoming ever more concentrated along the way.  It is argued (not by me) that this provided a remarkable opportunity for the virus to thrive and evolve amidst a large number of immune suppressed patients.  As the sick and wounded were moved from hospital to hospital, they may have carried flu variants with them, and when introduced into a new ward inoculated the patients already present with new strains.  Whether or not this story is an accurate rendition of the origin of the 1918 strain, it does get the brain ticking over.

What I find particularly troublesome in current events is the confluence of the H5N1 infections with a potential malaria outbreak resulting from conditions brought about by the tsunami.  There are two potential things that must happen in order for H5N1 to become truly dangerous to large populations.  The first is that it must find initial purchase in humans in order to replicate itself, and the second is that it must replicate in sufficient numbers and diversity to produce a more virulent strain.  The former is already happening on a small scale, as the human to human transmission cases illustrate.

But it is a virtual certainty that more people have been exposed to the virus than have become ill.  The immune systems of those who have escaped illness have been able to fight off the bug.  This means H5N1 hasn't had much of a chance to adapt itself to humans as hosts.  But what happens if H5N1 has the opportunity to infect large numbers of immune suppressed (or immune challenged) people?  I fear that this may come to pass if a malaria epidemic does strike areas affected by the tsunami.  H5N1 may thrive in such conditions, and whether its genome is altered by mutation or by recombination with other strains, variation and selection will definitely both be operating.  The parallels to the hypothetical origin of the 1918 flu are alarming, particularly in the context of modern rapid travel.

It would be nice if our knowledge of epidemiology and molecular biology could help us understand the probability of H5N1 becoming a pandemic-causing strain.  But as far as I can tell, we just don't know enough yet.  The furthest I have gone down this road is reading (and digesting as much as I could) a paper entitled, "Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses," by Chare et al, in the Journal of General Virology (2003, 84, 2691-2703).  This is a bioinformatic study of 79 gene sequence alignments from 35 negative sense RNA viruses, including the Spanish Flu. 

I can do no better to explain this paper than to quote from it;

Overall, our study reveals that recombination is unlikely to be a frequent process in negative-sense RNA viruses, with only a few clear-cut examples in the 79 gene sequence alignments studied here. While we were unable to estimate precise recombination rates from our analyses, it is clear that these rates must be lower than those of mutation, which is not the case in some other viruses. Indeed, the absence of any detectable recombination in 20 of 35 negative-sense RNA viruses suggests that they may be entirely clonal organisms, although this will clearly need to be confirmed with much larger sequence data sets.

It is important to reiterate this is essentially a theoretical study based on historical data.  The authors performed no experiments.  However nice our stories, making testable predictions and doing experiments are the only way we can get close to the truth.  If our models were better maybe we could get at a decent prediction for the behavior of H5N1.  Perhaps in turn this would enable a bit of practical planning in the field, as well as an estimate of the economic consequences of action and inaction.  The best we can do in this case is probably to marshall relevant historical, economic, and scientific stories, and perhaps combine this with some savy scenario planning.  But when it comes to nailing down details, we may just have to wait and see in this case.

We've picked up this story as an internal research project at Bio-Economic Research Associates.  If you are interested in contributing, or in supporting a more concentrated effort, let me know.

Going UP

Here are the first few paragraphs of my chapter for the Liftport Space Elevator Book (Official Title TBA), which will be published in summer 2005.  Loads of info and more documents at The Space Elevator Reference.


Construction and Operational Hazards to the Space Elevator
Robert Carlson

Climbing a narrow ribbon of carbon seems a tenuous means of reaching for the stars.  Like the horse hair suspending the sword over Damocles’ head, reminding him of the precarious nature of political power, the thin thread of the Space Elevator will constantly remind us of our fragile freedom from Earth’s gravity well.  The primary argument for building the elevator can be derived in a few lines on the back of an envelope; the energy cost of putting 1 kg in geosynchronous orbit on the elevator is approximately 1% the cost using rockets.  We then must determine whether the 100,000 km long structure is theoretically plausible to build and operate.
    Even in theory, the sheer size of the elevator inspires both awe and fear in the form of unknowns that appear overwhelming at first glance.  Fortunately we have accumulated many person-years of operational knowledge of the environments the ribbon will experience.  Moreover, all of the technology required to build the elevator has already been independently demonstrated, save the completed ribbon itself.  This means we can apply existing engineering know-how to evaluate whether the elevator is a feasible project and what risks may arise during construction and operation.  And the ribbon is far from being “unobtanium”.  There appears to be only one known material suitable for building the ribbon, carbon nanotubes (CNTs).  The amount of progress made in understanding both the construction and properties of long carbon nanotubes is quite remarkable given our mere 15 years of experience.  Many critical properties of the ribbon, and its constituent adhesives and CNTs, can already be measured or estimated. 
    Still, the history of human engineering and construction is full of hubris confronted by physics.  The devil is definitely in the details for this project.  The few engineering details available are compiled in two NASA Institute for Advanced Concepts (NIAC) reports and a book, all written by Bradley Edwards.
    The purpose of this chapter is to explore what could go wrong with the deployment and operational plans, and what might be done about it.  Much of those plans are determined by the seemingly unavoidable requirement of launching an initial full-length ribbon and then lowering it from orbit to the Earth’s surface.  As related in Brad Edwards' reports (Phase I, Phase II, book at Amazon) for NASA, this deployment strategy appears a happy confluence of economic and design factors.  The numbers, remarkably, work out quite nicely...

I'll post publication details for the book when they are finalized.

Tadpoles Unleashed

The first paper describing sensitive, parallel quantitation of "just about anything" using Tadpoles is now published.  "Using protein-DNA chimeras to detect and count small numbers of molecules"(abstract), is now available at Nature Methods.  The News and Views piece (subscription required), by Garry Nolan, a microbiology and immunology professor at Stanford, describes the paper thus;

What is important about the work is that [it] went well beyond the norm in providing proof of concept for a detection system. The modularity of [the] approach, the ease with which the recognition domains can be created and simply coupled to a DNA marker for multiplexed measurements, and the extraordinary sensitivity of the approach makes this an appealing system for researchers wanting a standardized high-throughput, and accurate, detection system for...just about anything.

It is gratifying to finally see this technology out in the world.  Ian Burbulis, in particular, did a tremendous job in grinding out the details of assembling the detector molecules and of making the assays work.  When Ian and I conceived this technology, the point was to enable multiplexed detection of proteins and other analytes from single cells.  While we have more work to do to implement the assay at the single cell level, the paper demonstrates we are well on our way.

Nolan also notes the commercial potential of the technology: "The authors [demonstrated] a more real-world, sensitive test of an important bacterial pathogen in whole blood sera.  I can already see the reagent vendors scrambling for their phones."  As one of the two inventors (here is the patent application), this gives me the opportunity to blog about the tension between protecting inventions, to enable commercialization, and the philosophy and practice of Open Source.  I first discussed the potential of widespread access to biological technology in "Open Source Biology And Its Impact on Industry", published in IEEE Spectrum in 2001.  More on this in an upcoming post.

"Carlson Curves" and Synthetic Biology

(UPDATE, 1 September 06: Here is a note about the recent Synthetic Biology story in The Economist.)

(UPDATE, 20 Feb 06: If you came here from Paul Boutin's story "Biowar for Dummies", I've noted a few corrections HERE.)

Oliver Morton's Wired Magazine article about Synthetic Biology is here. If you are looking for the "Carlson Curves", The Pace and Proliferation of Biological Technologies" is published in the journal Biosecurity and Bioterrorism. The paper is available in html at kurzweilai.net.

A note on the so-called "Carlson Curves" (Oliver Morton's phrase, not mine): The plots were meant to provide a sense of how changes in technology are bringing about improvements in productivity in the lab, rather than to provide a quantitative prediction of the future. I am not suggesting there will be a "Moore's Law" for biological technologies. Although it may be possible to extract doubling rates for some aspect of this technology, I don't know whether this analysis is very interesting. I prefer to keep it simple. As I explain in the paper, the time scale of changes in transistor density are set by planning and finance considerations for multi-billion dollar integrated circuit fabs. That doubling time has a significant influence on many billions of dollars of investment. Biology, on the other hand, is cheap, and change should come much faster. Money should be less and less of an issue as time goes on, and my guess is those curves provide a lower bound on changes in productivity.

I will try to have something tomorrow about George Church and Co's "unexpected improvement" in DNA synthesis capacity, as well as some comments about Nicholas Wade's New York Times story.

Up and running

Welcome. I am up to my neck in too many projects, but I will try to make it a priority to post here. Among other things, I hope to use this as a space to propose ideas, and solicit comments, that will eventually appear in a book.

Oliver Morton's Wired Magazine story on Synthetic Biology can be found here.

Those seeking information on "Carlson Curves" should visit http://www.synthesis.cc.